Aug 16, 2024 / 03:00AM GMT
Operator
Ladies and gentlemen, good morning, and welcome to the Q1 FY '25 earnings conference call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you, and over to you, sir.
Utkarsh Gandhi - Glenmark Pharmaceuticals Ltd - Investor Relations
Thank you, Lizanne. Good morning, everyone. Welcome to the Q1 FY '25 Results Conference Call of Glenmark Pharmaceuticals Limited. Before we start the Q&A, we'll review the performance of the company for the first quarter of FY '25.
For Q1 FY '25, Glenmark's consolidated revenue from operations was at INR 32,442 million as against INR 30,361 million in the corresponding quarter last year, recording a Y-o-Y growth of 6.9%. In terms of our overall performance across regions starting with India.
So for India, our formulation business recorded revenue of INR 11,962 million as against INR 10,693 million in the
Q1 2025 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Aug 16, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers